Download PDF
Thromb Haemost 1994; 72(03): 347-351
DOI: 10.1055/s-0038-1648869
Original Article
Schattauer GmbH Stuttgart

Assessment of Therapeutic Quality Control in a Long-Term Anticoagulant Trial in Post-Myocardial Infarction Patients

Aida J Azar
1   The Thoraxcenter, Department of Cardiology, University Hospital Dijkzigt, Erasmus University of Rotterdam, The Netherlands
2   ASPECT Coordinating Centre, Rotterdam, The Netherlands
,
Jaap W Deckers
1   The Thoraxcenter, Department of Cardiology, University Hospital Dijkzigt, Erasmus University of Rotterdam, The Netherlands
,
Frits R Rosendaal
3   The Thrombosis and Haemostasis Research Centre, Academic Hospital Leiden, The Netherlands
,
Paul F M M van Bergen
2   ASPECT Coordinating Centre, Rotterdam, The Netherlands
,
Felix J M van der Meer
3   The Thrombosis and Haemostasis Research Centre, Academic Hospital Leiden, The Netherlands
,
Jan J C Jonker
2   ASPECT Coordinating Centre, Rotterdam, The Netherlands
,
Ernest Briëf
3   The Thrombosis and Haemostasis Research Centre, Academic Hospital Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 21 December 1993

Accepted after revision 03 June 1994

Publication Date:
25 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Various methods have been described to evaluate efficacy of anticoagulant therapy using the international normalized ration (INR). We compared the following approaches: (1) total INR’s or the most recent measurement; (2) percent time within therapeutic range, with INR changing directly or halfway between visits; and (3) total observation time assuming INR changing linearly. The study population comprised 1700 post myocardial infarction patients. Treatment comprised 3725 patient-years. There were 61,471 INR assessments with target therapeutic level of 2.8–4.8. Acenocoumarol as well as phenprocoumon were employed. Therapeutic achievement in the first months of treatment was low: less than 60% of INR’s were in range. Treatment stabilized after 6 months. Patients on acenocoumarol were within range 70% of the time compared to 80% for phenprocoumon. Method 3 is preferred because it incorporates time and is capable of calculating incidence rates at different INR levels. Our findings call for an urgent improvement of standard of anticoagulant control in the first months following commencement of treatment.

 

  • References

  • 1 Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-1875
    CrossrefPubMedGoogle Scholar
  • 2 Poller L, Hirsh J. Optimal therapeutic ranges for oral anticoagulation. In: Thrombosis in cardiovascular disorders Fuster V, Verstraete M. eds Philadelphia: W. B. Saunders Company; 1992: 161-73
  • 3 vd Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993; 153: 1557-1562
    CrossrefPubMedGoogle Scholar
  • 4 Kirkwood TBL. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983; 49: 238-244
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Loeliger EA. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985; 53: 155-156
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Loeliger EA: Laboratory control, optimal therapeutic ranges and therapeutic quality control in oral anticoagulation. Acta Haematol 1985; 74: 125-131
    CrossrefPubMedGoogle Scholar
  • 7 Loeliger EA, Broekmans AW. Optimal therapeutic anticoagulation. Haemostasis 1985; 15: 283-292
    PubMedGoogle Scholar
  • 8 Poller L. Optimal therapeutic range for oral anticoagulation. In: Recent advances in blood coagulation Poller L. ed Edinburgh: Churchill Livingstone; 1991: 245-264
  • 9 Davis FB, Estruch MT, Samson-Corvera EB, Voigt GC, Tobin JD. Management of anticoagulation in outpatients. Experience with ananticoagulation service in a municipal hospital setting. Arch Intern Med 1977; 137: 197-202
    CrossrefPubMedGoogle Scholar
  • 10 Forfar JC. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. Br Heart J 1979; 42: 128-132
    CrossrefPubMedGoogle Scholar
  • 11 Harries AD, Birtwell AJ. Jones DB: Anticoagulant control. Letter to the editor. Lancet 1981; 2: 1320
    PubMedGoogle Scholar
  • 12 The Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; 2: 989-993
    PubMedGoogle Scholar
  • 13 Mclnnes GT. Efficacy of anticoagulation in the U. K. Letter to the editor. Lancet 1981; 2: 88
    PubMedGoogle Scholar
  • 14 Majumdar G, Payne RW. Quality of oral anticoagulant therapy. Clin Lab Haematol 1985; 7: 125-131
    CrossrefPubMedGoogle Scholar
  • 15 Wickramasinghe LSP, Basu SK, Bansal SK. Long-term oral anticoagulant therapy in elderly patients. Age and Ageing 1988; 17: 388-396
    CrossrefPubMedGoogle Scholar
  • 16 Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-152
    CrossrefPubMedGoogle Scholar
  • 17 van den Besselaar AMPH, van der Meer FJM, Gerrits-Drabbe CW. Therapeutic control of oral anticoagulant treatment in the Netherlands. Am J Clin Pathol 1988; 90: 685-690
    CrossrefPubMedGoogle Scholar
  • 18 van den Besselaar AMPH. Recommended method for reporting therapeutic control of oral anticoagulant therapy. Thromb Haemost 1990; 63: 316-317
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Broekmans AW, Loeliger EA. Therapeutic control of anticoagulant treatment. Letter to the editor. Br Med J 1982; 284: 1330-13331
    PubMedGoogle Scholar
  • 20 Duxbury BMcD. Therapeutic quality control leading to further clinical assessment of oral anticoagulation. Acta Haematol 1986; 76: 65-67
    CrossrefPubMedGoogle Scholar
  • 21 Duxbury BMcD. Therapeutic control of anticoagulant treatment. Letter to the editor. Br Med J 1982; 284: 1634-1635
    PubMedGoogle Scholar
  • 22 Copplestone A, Roath S. Assessment of therapeutic control of anticoagulation. Acta Haematol 1984; 71: 376-380
    CrossrefPubMedGoogle Scholar
  • 23 Raper CGL. The therapeutic control of anticoagulant clinics. Letter to the Editor. Clin Lab Haematol 1983; 5: 325-327
    PubMedGoogle Scholar
  • 24 Rosendaal FR, Cannegieter SC, vd Meer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Cannegieter SC, Rosendaal FR, Briet E. The optimal intensity of oral anticoagulant therapy in patients with prothetic heart valves (abstract). Thromb Res 1992; 65: 80
    PubMedGoogle Scholar
  • 26 Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research group. Effect of long-term anticoagulant treatment on mortality an cardiovascular morbidity after myocardial infarction. Lancet 1994; 1: 499-503
    PubMedGoogle Scholar
  • 27 Loeliger EA, Lewis SM. Progress in laboratory control of oral anticoagulants. Lancet 1982; 2: 318-320
    PubMedGoogle Scholar
  • 28 Rozenberg MC, Kronenberg H, Firkin BG. “Thrombotest” and prothrombin time: a controlled clinical trial. Aust Ann Med 1965; 14: 3-12
    PubMedGoogle Scholar
  • 29 Wiegeman H, Vossepoel AM. A computer program for long-term anticoagulation control. Comput Programs Biomed 1977; 7: 71-84
    CrossrefPubMedGoogle Scholar
  • 30 Walker SH, Duncan DB. Estimation of the probability of an event as a function of several independent variables. Biometrika 1967; 54: 167-179
    CrossrefPubMedGoogle Scholar
  • 31 Azar AJ. Therapeutic achievement with long-term oral anticoagulants in post myocardial infarction patients.Dissertation. Erasmus University Rotterdam, The Netherlands 1993
    PubMedGoogle Scholar
  • 32 Fekkes N, de Jonde H, Veltkamp JJ, Bieger R, Loeliger EA. Comparative study of the clinical effect of acenocoumarol and phenprocoumon in myocardial infarction and angina pectoris. Acta Med Scand 1971; 190: 535-540
    PubMedGoogle Scholar